REVIEW

Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention [version 1; peer review: 2 approved]

Shayan Cheraghlou1-3, Young Lim1-3, Keith Choate1-3

1Department of Dermatology, Yale School of Medicine, New Haven, CT, USA
2Department of Pathology, Yale School of Medicine, New Haven, CT, USA
3Department of Genetics, Yale School of Medicine, New Haven, CT, USA

Abstract
Vascular tumors are neoplasms of endothelial cells, a significant number of which present in childhood. Recent studies have examined the mutational landscape of many subtypes of vascular tumors, identifying mutations primarily within the Ras–mitogen-activated protein kinase (MAPK) pathway and providing a unique opportunity to consider targeted therapeutics. This review will summarize the current understanding of childhood vascular tumor pathobiology.

Keywords
vascular tumors; vascular tumor management; genetics; hemangioma; Ras; MAPK; GNA14; GNA11; GNAQ; IDH

Open Peer Review

Referee Status: ✔️ ✔️

Invited Referees

1 Joyce Bischoff, Boston Children's Hospital, Harvard Medical School, USA
2 Douglas A. Marchuck, Duke University Medical Center, USA

Any comments on the article can be found at the end of the article.
Corresponding author: Keith Choate (keith.choate@yale.edu)

Author roles: Cheraghlou S: Conceptualization, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Lim Y: Conceptualization, Visualization, Writing – Review & Editing; Choate K: Conceptualization, Project Administration, Resources, Supervision, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The work for this report was supported by the Leon Rosenberg, M.D., Medical Student Research Fund in Genetics and the Jane Danowski Weiss Family Foundation Fellowship at the Yale University School of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Cheraghlou S et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Cheraghlou S, Lim Y and Choate K. Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention [version 1; peer review: 2 approved] F1000Research 2019, 8(F1000 Faculty Rev):590 (https://doi.org/10.12688/f1000research.16160.1)

First published: 30 Apr 2019, 8(F1000 Faculty Rev):590 (https://doi.org/10.12688/f1000research.16160.1)
Introduction
Vascular anomalies are divided into two groups: malformations and tumors. The most recent International Society for the Study of Vascular Anomalies (ISSVA) classification for vascular tumors further subdivides them into three primary groups: benign tumors, locally aggressive or borderline tumors, and malignant tumors (Table 1).

Infantile hemangiomas
Infantile hemangioma (IH) is the most common childhood vascular neoplasm; IH has an incidence of approximately 4.5% by 3 months of age. However, the genetic mechanism of IH pathobiology remains unknown despite its prevalence. In 1999, Walter et al. mapped a familial form of IH to 5q31-33, housing three candidate genes—fibroblast growth factor receptor-4 (FGFR4), platelet-derived growth factor receptor-β (PDGF-β), and fms-related tyrosine kinase-4 (FLT4)—and in subsequent work found that a small number of IHs (2 out of 15 studied cases) harbor somatic mutations in vascular endothelial growth factor (VEGF)-receptor 2 (p.P1147S) and VEGFR3 (p.P954S) (also known as FLT4). Nonetheless, these variants have yet to be confirmed via in vitro or in vivo studies to cause vascular tumors or oncogenic transformation. However, a recent single-nucleotide polymorphism (SNP) study of VEGFR-2 and VEGF-A in IH was unable to detect variants associated with disease, although the G allele of rs2010963 in VEGF-A was associated with a significantly lower risk of IH. Additionally, there is some debate regarding the sporadic or familial etiology of IH. Whereas twin studies suggest extra-genetic factors as the primary cause of disease, recent work studying multiple pedigrees suggests an either autosomal dominant or maternally transmitted inheritance pattern. Genetic analysis of syndromic forms of IH, including PHACE syndrome (posterior fossa malformations, infantile hemangiomas, arterial anomalies, cardiac defects, and eye anomalies syndrome), which appears more often in female offspring, suggests a possible X-linked recessive pattern but has not identified a somatic mutation associated with most cases. Similarly, a causative mutation has not yet been identified in LUMBAR syndrome (lower body hemangioma, urogenital malformation, myelopathy, bony deformities, anorectal malformations, arterial anomalies, and renal anomalies syndrome). The three leading hypotheses on the pathogenesis of IH are (1) local hypoxemia leading to hypoxia-inducible factor 1 alpha (HIF-1α)-induced proliferation, (2) embolization of placental cells, and (3) vasculogenesis/angiogenesis driven by hypoxemia-induced differentiation of mesenchymal stem cells into endothelial cells and Notch-mediated differentiation of mesenchymal stem cells into proangiogenic pericytes. These hypotheses do not address the multi-system defects found in PHACE or LUMBAR syndromes which suggest that somatic mosaicism plays a role in pathogenesis.

Table 1. International Society for the Study of Vascular Anomalies (ISSVA) classification of vascular tumors.

| Benign vascular tumors                                      | Infantile hemangiomas                  |
|------------------------------------------------------------|----------------------------------------|
|                                                           | Congenital hemangioma (CH)             |
|                                                           | Rapidly involuting CH                  |
|                                                           | Non-involuting CH                      |
|                                                           | Partially involuting CH                |
|                                                           | Tufted angioma                         |
|                                                           | Spindle cell hemangioma                |
|                                                           | Epithelioid hemangioma                 |
|                                                           | Lobular capillary hemangiomas (pyogenic granuloma) |
|                                                           | Others                                 |
| Locally aggressive or borderline vascular tumors           | Kaposiform hemangioendothelioma         |
|                                                           | Retiform hemangioendothelioma          |
|                                                           | Papillary intralymphatic angioendothelioma |
|                                                           | Composite hemangioendothelioma         |
|                                                           | Pseudomyogenic hemangioendothelioma    |
|                                                           | Polymorphous hemangioendothelioma      |
|                                                           | Hemangioendothelioma and not otherwise specified |
|                                                           | Kaposi sarcoma                         |
|                                                           | Others                                 |
| Malignant vascular tumors                                  | Angiosarcoma                           |
|                                                           | Epithelioid hemangioendothelioma       |
|                                                           | Others                                 |
Unlike other childhood vascular tumors, IH responds to beta-blockers; 60% of patients experience complete or near-complete resolution of the lesion and 88% of patients demonstrate improvement following a 6-month course of propranolol at a dose of 3 mg/kg per day. Prior to the advent of beta-blockers in the treatment of IH, treatment with systemic corticosteroids was considered the standard of care, and a pooled meta-analysis estimated that 69% of lesions respond to therapy, although significant morbidity—including Cushingoid features, gastrointestinal reflux, hypertension, ulceration, bleeding, failure to thrive, hirsutism, hypercholesterolemia, and infection—was also reported. IH can also be distinguished from other tumors by its positive GLUT1 immunoreactivity; up to 97% of lesions show positive signal. Notably, however, about half of the vessels in a given tumor are GLUT1-negative, suggesting that a heterogeneous population of endothelial cells populates these lesions, an idea later confirmed by in vitro studies of cells isolated from IH samples. Although the genetic factors contributing to IH pathobiology remain unknown, many somatic mutations associated with GLUT1-negative vascular tumors have been identified in recent years, most in genes already known to be implicated in tumorigenesis.

IDH1/IDH2

Genetic insight into spindle cell hemangiomas (SCHs) came from studies of Maffucci syndrome (Spranger type II enchondromatosis), a subtype of enchondromatosis presenting with multiple SCHs in early childhood. In an analysis of 13 patients with Maffucci syndrome, Pansuriya et al. found that 70% of SCHs had p.R132C mutations in exon 4 of isocitrate dehydrogenase 1 (IDH1). Given the disorder’s unilateral distribution of the enchondromas, the lack of mutations detected in adjacent non-lesional tissue, the absence of transmission within pedigrees, and the identification of tissue-specific IDH1 mutations, somatic mosaicism was considered causal. Further work in sporadic, acquired SCH found that IDH1 p.R132C is found in at least 64% of cases. Among cases negative for IDH1 p.R132C, 20% had mutations at arginine 172 in exon 4 of IDH2, suggesting genetic heterogeneity.

Mutations in exon 4 at arginine 132 of IDH1 or at arginine 140 or 172 of IDH2 lead to the production of 2-hydroxyglutarate, an oncometabolite which causes a hypermethylation phenotype leading to the inhibition of genes responsible for terminal differentiation. Additionally, mutations in IDH1 found in gliomas lead to reduction of alpha-ketoglutarate production, inducing HIF-1α, which drives tumor growth via the hypoxia pathway. Interestingly, analysis of HIF-1α in SCH revealed a lack of expression in all samples, suggesting that IDH1 and IDH2 mutations driving SCH may act via a distinct mechanism.

CAMTA1/TFE

Of childhood vascular tumors, epithelioid hemangioendothelioma (EHE) is the most common malignant variety. In 2001, Mendick et al. reported an identical chromosomal translocation of (1;3) (p36.3;q25) in two cases of EHE. Owing to low tumorcellularity and the absence of EHE cell lines, the specific genes disrupted via the translocation remained unknown until 2011, when Tanas et al. employed RNA sequencing to identify a fusion between the promoter region of WW domain-containing transcription regulator 1 (WWTR1) on 3q25 and the carboxyl terminus of calmodulin-binding transcription activator 1 (CAMTA1) on 1p36. Given the high activity of the WWTR1 promoter in endothelial cells and the ectopic expression of CAMTA1, which is typically found only in brain tissue, the authors hypothesized that WWTR1/CAMTA1 functions as an oncogene via a promoter switch mechanism. Further work found that the WWTR1-CAMTA1 fusion is a consistent genetic finding in EHEs of different anatomic subsites.

In EHE samples without a WWTR1-CAMTA1 mutation, a distinct gene fusion between transcription factor E3 (TFE) and yes-associated protein 1 (YAP1) was identified. Given the structural and functional similarities between YAP1 and WWTR1 as well as the oncogenic nature of TFE3 with preserved transcriptional activation domains, well recognized in other cancers, a promoter switch similar to that of WWTR1-CAMTA1 fusions is hypothesized to underlie oncogenesis in cases with YAP1-TFE3 fusions.

GNA family

In recent years, a number of studies have highlighted the importance of the Ras–mitogen-activated protein kinase (MAPK) pathway in the oncogenic transformation of many childhood vascular tumors (Figure 1). The most upstream portion of the pathway elucidated thus far is the guanine nucleotide-binding subunit alpha q (Gnaq) family of genes: GNAQ, GNA11, and GNA14. In 2016, three studies demonstrated that somatic activating mutations in these genes are found in congenital hemangioma (including both rapidly involuting congenital hemangiomas and non-involuting congenital hemangiomas), kaposiform hemangioendotheliomas (KHEs), congenital tufted angiommas (TAs), and childhood lobular capillary hemangiomas (LCHs) via whole-exome sequencing. Activating mutations at the arginine 183 position of GNA11 and the glutamine 209 position of GNA11 and GNAQ were also found in several cases of sporadic congenital hemangioma, while mutation of glutamine 205 in GNA14, the analogous position of glutamine 209 in GNA11 and GNAQ, was found in one case each of KHE, LCH, and TA.

Recent work has also identified mutations in the glutamine 205 position of GNA14 and the glutamine 209 position of GNAQ in anastomosing hemangiomas. Although these mutations have been demonstrated to cause cell morphology changes, upregulation of biochemical growth pathways, and acquisition of growth factor independence in vitro, they have not yet been shown to cause disease in an in vivo model. Notably, arginine 183 mutation in GNAQ is thought to be responsible for up to 88% of Sturge–Weber syndrome which presents with port-wine stains (PWSs) and leptomeningeal vascular malformations, while similar GNA11 and GNAQ activating mutations underlie 77% of capillary malformations, 46% of uveal melanomas, and 83% of blue nevi. Activated GNA11 and GNAQ are thought to mediate VEGFR-2 phosphorylation, triggering human umbilical vein endothelial cell (HUVEC) proliferation in vitro.

These Gα-subunit proteins exchange bound GDP for GTP when their associated G protein–coupled receptor (GPCR) is activated, leading to dissociation of the G-protein...
heterotrimer—composed of G\textsubscript{\alpha}, G\textsubscript{\beta}, and G\textsubscript{\gamma}—from the GPCR and of the activated G\textsubscript{\alpha} subunit from the G\textsubscript{\beta}/G\textsubscript{\gamma} dimer, ultimately leading to the downstream activation of several cellular pathways.

The mechanism of tumorigenesis associated with these mutations can provide insights into targeted therapeutics. G\textsubscript{\alpha} is upstream of both the Ras-MAPK and the PI3K-Akt-mTOR, and previous studies of low-flow, lymphatic/venous, vascular malformations implicated the PI3K-Akt-mTOR pathway as the primary driver of these lesions\textsuperscript{56–59}. Although sirolimus is effective in the treatment of these low-flow lesions\textsuperscript{60–63}, it has shown little efficacy in vascular tumors, suggesting a distinct pathobiology\textsuperscript{62,64,65}. In a study using primary HUVECs expressing mutant G\textsubscript{NA11} and G\textsubscript{NA14}, cells showed no indication of PI3K-Akt-mTOR pathway activation (as measured by pAKT) and instead showed specific activation of the Ras-MAPK pathway (via increased pERK)\textsuperscript{47}, suggesting that a more effective therapy may involve targeting the Ras-MAPK pathway. Recent work suggests that high-flow arteriovenous malformations (AVMs) are also driven by mutations within the Ras-MAPK signaling pathway\textsuperscript{66}. Thus, advances in therapy for vascular tumors may also benefit patients with these high-flow vascular malformations. Somatic mutations in downstream components of this pathway in other vascular tumors further highlight the Ras-MAPK pathway as a primary driver of tumorigenesis in childhood vascular tumors.

The MAPK pathway
Activation of G\textsubscript{\alpha} leads to increased RAS activation\textsuperscript{67}. Indeed, a study of sporadic LCHs identified somatic mutations in all three subgroups of the RAS subfamily: HRAS, KRAS, and NRAS\textsuperscript{68}. The activating mutations, which mainly fall at codons 12, 13, and 61, have been established to generate constitutive Ras-MAPK signaling by preventing GTP hydrolysis\textsuperscript{69}. Furthermore, a study of LCHs arising within PWS also identified a p.V600E mutation in BRAF, a proto-oncogene directly downstream of Ras in the MAPK pathway chain\textsuperscript{70}. Interestingly, the study also found that both the underlying PWS and the LCH carried mutations in the arginine 183 position of GNAQ but that BRAF or RAS mutation was specific to the LCHs, suggesting that the LCHs arose because of a “second-hit” in RAS or BRAF.

Mutations in the Fos family of transcription factors, which are among the final components of the Ras-MAPK pathway, have also been identified in childhood vascular tumors. Cytogenetic study of pseudomyogenic hemangiendothelioma (PHE) revealed a t(7;19) (q22;q13) translocation as the sole anomaly in three lesions from one patient\textsuperscript{71}. Later study of this patient and an additional case of PHE revealed that this translocation leads to a SERPINE1-FOSB fusion gene\textsuperscript{72}. Although vascular endothelial cells demonstrate strong endogenous expression of SERPINE1, the SERPINE1–FOSB disrupts the protein-coding...
portion of the SERPINE1 gene, instead generating high levels of FOSB mRNA via a promoter switch mechanism. FOSS and FOS mutations have also been identified in cases of epithelioid hemangioma (EH). In one study of EH, Antonescu et al. identified two fusion genes: WWTR1/FOSB and ZFP36/FOSB. It has also been demonstrated that the FOS rearrangement leading to the truncation of the FOS protein, specifically to loss of the transactivation domain (TAD), leads to EH in bone.

Summary
The highlighted genetic discoveries in vascular tumor biology provide novel targets for therapeutics. Indeed, the fact that most of these mutations are present in known cancer-causing pathways means that many medications that are currently approved or under trial for other malignancies may be repurposed for use in vascular tumor therapy.

Mutations in IDH are known to cause gliomas, glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies in addition to SChs. As such, a number of therapeutics currently under investigation may also be effective in the treatment of SCh. Early results from trials of iodosenib (AG-120), a novel inhibitor of mutant IDH1, in IDH1-mutated acute myelogenous leukemia (AML) indicated an overall response rate of 41.6% and a complete remission rate of 21.6%. Similarly, results from early trials of enasib (AG-221), a novel inhibitor of mutant IDH2, in IDH2-mutated AML indicated an overall response rate of 40.3% and a complete remission rate of 19.3%. These agents are currently under study in a number of clinical trials (ClinicalTrials.gov Identifiers: NCT02074839, NCT02073994, NCT01915498, NCT02577406, NCT02632708, and NCT02677922). Mouse studies have also shown potential for an IDH1 peptide vaccine, which is currently under trial (ClinicalTrials.gov Identifiers: NCT02454634 and NCT02193347).

Selective inhibition of the Ras-MAPK pathway may provide a novel therapeutic avenue for childhood vascular lesions, which currently have few effective non-surgical options. The central role of this pathway in tumor pathobiology has necessitated the development of a number of currently available medications, including farnesyl transferase inhibitors such as salirasib, BRAF inhibitors such as vemurafenib, MEK inhibitors such as trametinib, and ERK inhibitors such as ulixertinib, which warrant further study as therapy for childhood vascular tumors. Indeed, Al-Olabi et al. demonstrated that treatment of AVMs in BRAF-mutant zebrafish with vemurafenib leads to restoration of blood flow in AVMs where it was previously limited. With promising early results, these therapies hold great potential for the treatment of childhood vascular tumors.

Grant information
The work for this report was supported by the Leon Rosenberg, M.D., Medical Student Research Fund in Genetics and the Jane Danowski Weiss Family Foundation Fellowship at the Yale University School of Medicine.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Mulliken JB, Glowacki J: Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982; 69(3): 412–22. PubMed Abstract | Publisher Full Text
2. Kanada KN, Merin MR, Munden A, et al: A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr. 2012; 161(2): 240–5. PubMed Abstract | Publisher Full Text
3. Walter JW, Blei F, Anderson JL, et al: Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet. 1999; 82(1): 77–83. PubMed Abstract | Publisher Full Text
4. Walter JW, North PE, Waner M, et al: Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer. 2002; 33(3): 295–303. PubMed Abstract | Publisher Full Text
5. Oszała C, Šmějkal J, Wyrzykowski D, et al: Single-nucleotide polymorphisms of VEGF-A and VEGFR-3 genes and risk of infantile hemangioma. Int J Dermatol. 2016; 55(9): 1201–7. PubMed Abstract | Publisher Full Text | F1000 Recommendation
6. Cheung DS, Warman ML, Mulliken JB: Hemangioma in twins. Ann Plast Surg. 1997; 38(3): 269–74. PubMed Abstract | Publisher Full Text | F1000 Recommendation
7. Castellana E, Salminen P, Väkänen M, et al: Inheritance Patterns of Infantile Hemangioma. Pediatrics. 2016; 138(5): pii: e20161623. PubMed Abstract | Publisher Full Text | F1000 Recommendation
8. Frieden IJ, Reese V, Cohen D: PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996; 132(3): 307–11. PubMed Abstract | Publisher Full Text
9. Siegel DH, Shieh JTC, Kwon EK, et al: Copy number variation analysis in 98 individuals with PHACE syndrome. J Invest Dermatol. 2013; 133(3): 677–84. PubMed Abstract | Publisher Full Text | Free Full Text
10. Mitchell S, Siegel DH, Shieh JT, et al: Candidate locus analysis for PHACE syndrome. Am J Med Genet A. 2012; 158A(6): 1363–7. PubMed Abstract | Publisher Full Text | Free Full Text
11. Iacobas I, Burrows PE, Frieden UJ, et al: LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010; 157(5): 795–801. PubMed Abstract | Publisher Full Text
12. Kleinman ME, Greives MR, Chargin SS, et al: Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol. 2007; 27(12): 2664–70. PubMed Abstract | Publisher Full Text
13. Chang EJ, Chang EI, Thangarajah H, et al: Hypoxia, Hormones, and Endothelial Progenitor Cells in Hemangioma. Lymphat Res Biol. 2007; 5(4): 237–43. PubMed Abstract | Publisher Full Text
14. Barnés CM, Huang S, Kaipainen A, et al: Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A. 2005; 102(52): 19097–102. PubMed Abstract | Publisher Full Text | Free Full Text
15. Barnés CM, Christopher-Layay EA, Folkman J: The placenta theory and the origin of infantile hemangioma. Lymphat Res Biol. 2007; 5(4): 245–55. PubMed Abstract | Publisher Full Text
16. Mihm MC Jr, Nelson JS: Hypothesis: The metastatic niche theory can elucidate infantile hemangioma development. J Cutan Pathol. 2010; 37 Suppl 1: 83–7.

PubMed Abstract | Publisher Full Text | Free Full Text

17. North PE, Wamer W, Mizeracki A, et al.: GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31(1): 11–22.

PubMed Abstract | Publisher Full Text | Free Full Text

18. Greenberger S, Bischof J: Pathogenesis of infantile haemangioma. Br J Dermatol. 2013; 169(1): 12–9.

PubMed Abstract | Publisher Full Text | Free Full Text

19. Boye E, Yu Y, Paranya G, et al.: Clonality and altered behavior of endothelial cells from infantile hemangiomas. J Clin Invest. 2001; 107(6): 745–52.

PubMed Abstract | Publisher Full Text | Free Full Text

20. Boscolo E, Stewart CL, Greenberger S, et al.: JAGGED1 Signaling Regulates Hemangioma Stem Cell–to–Pericyte/Vascular Smooth Muscle Cell Differentiation. Arterioscler Thromb Vasc Biol. 2011; 31(10): 2181–92.

PubMed Abstract | Publisher Full Text | Free Full Text

21. Wu JK, Adepoju O, De Silva D, et al.: A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. Angiogenesis. 2010; 13(1): 15–23.

PubMed Abstract | Publisher Full Text | Free Full Text

22. Boscolo E, Mulliken JB, Bischof J: Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1, Arterioscler Thromb Vasc Biol. 2013; 33(3): 501–9.

PubMed Abstract | Publisher Full Text | Free Full Text

23. Wassef M, Blei F, Adams D, et al.: Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics. 2015; 136(1): e203–14.

PubMed Abstract | Publisher Full Text

24. Leault-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al.: Pericytes from infantile hemangioma display a unique microvascular phenotype paralleling stem cell to endothelial transition in infantile hemangioma. J Pediatr Surg. 2015; 50(3): 688–94.

PubMed Abstract | Publisher Full Text | Free Full Text

25. Aydurk UM, Couto JA, Hann S, et al.: Somatotrophic Bahraini and Congenital Hemangioma–Associated With a Somatic Activating Mutation in GNA11. JAMA Dermatol. 2016; 152(9): 1015–20.

PubMed Abstract | Publisher Full Text

26. Hull K, Nakayama H, Klagsbrun M, et al.: IDH1 catalytic activity and induce HIF-1alpha.

PubMed Abstract

27. Tenno R, Song Y, Yuan L, et al.: The glioma hypermethylator phenotype. Nature. 2010; 462(7279): 739–44.

PubMed Abstract | Publisher Full Text | Free Full Text

28. Lacasse C, Huang L, Nakayama H, Klagsbrun M, et al.: IDH1 mutation induces a glioma hypermethylator phenotype. Nature. 2012; 483(7390): 474–8.

PubMed Abstract | Publisher Full Text | Free Full Text

29. Zhao L, Sun Y, Xu W, et al.: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009; 324(5934): 261-5.

PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

30. Mendick MR, Nelson M, Pickering D, et al.: Translocation t(1;13)(p36.3;q25) is a nonrandom aberration in epitheloid hemangiendothelioma. Am J Surg Pathol. 2001; 25(5): 684–7.

PubMed Abstract | Publisher Full Text

31. Tanas MR, Stoner A, Oliveira AM, et al.: Identification of a disease-defining gene fusion in epitheloid hemangiendothelioma. Sci Transl Med. 2011; 3(86): 89a82.

PubMed Abstract | Publisher Full Text

32. Errani C, Zhang L, Suri YS, et al.: A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epitheloid hemangiendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011; 50(8): 644–53.

PubMed Abstract | Publisher Full Text

33. Antonescu CR, Le Loarer F, Mosquera JM, et al.: Novel YAP1-TFE3 fusion defines a distinct subset of epitheloid hemangiendothelioma. Genes Chromosomes Cancer. 2012; 52(8): 775–84.

PubMed Abstract | Publisher Full Text | Free Full Text

34. Sidhar SK, Clark J, Gill S, et al.: The T(1;1)(p11.2;q12.1) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet. 1996; 5(9): 1333–8.

PubMed Abstract | Publisher Full Text

35. Clark J, Lu YJ, Sidhar SK, et al.: Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene. 1997; 16(18): 2233–4.

PubMed Abstract | Publisher Full Text

36. Ladanyi M, Lui MY, Antonescu CR, et al.: The der(17)(t(17;11)(p12;q25) of human alopecia areata soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001; 20(1): 48–57.

PubMed Abstract | Publisher Full Text

37. Furr T, Lim Y, Kulongowski AM, et al.: Symptomatic Congenital Hemangioma and Congenital Hemangiomas Associated With a Somatic Activating Mutation in GNA11, JAMA Dermatol. 2015; 152(9): 1015–20.

PubMed Abstract | Publisher Full Text

38. Ayturk UM, Couto JA, Hann S, et al.: Somatotrophic Mutations in GNAQ and GNA11 Are Associated With Congenital Hemangioma. Am J Hum Genet. 2016; 98(4): 789–95.

PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

39. Lim YH, Bachoo RC, Qiu J, et al.: GNA14 Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation. Am J Hum Genet. 2016; 99(2): 443–50.

PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

40. Bean GR, Joseph NM, Folpe AL, et al.: Recurrent GNA14 mutations in anastomosing haemangiomatous, Histopathology 2019; 133(2): 354–7.

PubMed Abstract | Publisher Full Text | F1000 Recommendation

41. Nakashima M, Miyajima M, Sugano H, et al.: The somatic GNAQ mutation c.5480A>G (p.R183Q) is consistently found in Sturge-Weber syndrome. J Hum Genet. 2014; 59(12): 691–3.

PubMed Abstract | Publisher Full Text

42. Couto JA, Huang L, Vivero MP, et al.: Endothelial Cells from Capillary Malformations Are Enriched for Somatic GNAQ Mutations. Plast Reconstr Surg. 2016; 137(1): 77e–82e.

PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

43. Van Raamsdonk CD, Bezrookove V, Green G, et al.: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009; 457(7229): 599–602.

PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

44. Shirley MD, Tang H, Galione CJ, et al.: Sturge-Weber syndrome and portwine stains caused by somatic mutation in GNAQ. Nat Engl J Med. 2013; 368(21): 1971–9.

PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

45. Zeng H, Zhao D, Yang S, et al.: Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling. J Biol Chem. 2003; 278(23): 20736–45.

PubMed Abstract | Publisher Full Text

46. Wettsteinbch M, Offermanns M: Mammalian G proteins and their cell type specific functions. Physiol Rev. 2000; 80(5): 1169–204.

PubMed Abstract | Publisher Full Text

47. Hubbard KB, Hepler JR: Cell signalling diversity of the Gqalpha family of G protein-coupled receptors. Nat Rev Mol Cell Biol. 2002; 3(1): 26–34.

PubMed Abstract | Publisher Full Text

48. Osborn AJ, Dickie P, Neilson DE, et al.: The somatic mosaic nature of infantile haemangioma. J Mol Med. 2010; 88(6): 787–96.

PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

49. Lüks VL, Kamiński N, Vivero MP, et al.: Lymphatic and other vascular
malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015; 166(4): 1048–54.e1–5. PubMed Abstract | Publisher Full Text | Free Full Text

60. Hammill AM, Wentzel M, Gupta A, et al.: Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011; 57(6): 1018–24. PubMed Abstract | Publisher Full Text | F1000 Recommendation

61. Yukselkaya H, Ozbek O, Kesar M, et al.: Blue rubber bleb nevus syndrome: successful treatment with sirolimus. Pediatrics. 2012; 129(4): e1080–e1084. PubMed Abstract | Publisher Full Text

62. Boscolo E, Limaye N, Huang L, et al.: Sirolimus in the Treatment of Vascular Anomalies. Eur J Pediatr Surg. 2017; 27(1): 86–90. PubMed Abstract | Publisher Full Text | F1000 Recommendation

63. Boscolo E, Limaye N, Huang L, et al.: Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest. 2015; 125(9): 3491–504. PubMed Abstract | Publisher Full Text | F1000 Recommendation

64. Adams DM, Trenor CC 3rd, Hammill AM, et al.: Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. 2016; 137(2): e20153257. PubMed Abstract | Publisher Full Text | F1000 Recommendation

65. Lackner H, Karastaneva A, Schwinger W, et al.: Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr. 2015; 174(12): 1579–84. PubMed Abstract | Publisher Full Text | F1000 Recommendation

66. Couto JA, Huang AY, Korczyn DJ, et al.: Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation. Am J Hum Genet. 2017; 100(3): 546–54. PubMed Abstract | Publisher Full Text | F1000 Recommendation

67. Kwan DH, Yung LY, Ye RD, et al.: Activation of Ras-dependent signaling pathways by Gαi-coupled receptors requires the adaptor protein TPR1. J Cell Biochem. 2012; 113(11): 3486–97. PubMed Abstract | Publisher Full Text

68. Lim YH, Douglas SR, Ko CJ, et al.: Somatic Activating RAS Mutations Cause Vascular Tumors Including Pyogenic Granuloma. J Invest Dermatol. 2015; 135(6): 1698–700. PubMed Abstract | Publisher Full Text | Free Full Text

69. Bos JL: ras oncogenes in human cancer: a review. Cancer Res. 1989; 49(17): 4682–9. PubMed Abstract

70. Groesser L, Peterhof E, Evert M, et al.: BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma. J Invest Dermatol. 2016; 138(2): 481–6. PubMed Abstract | Publisher Full Text | F1000 Recommendation

71. Trombetta D, Magnuson L, von Steyem FV, et al.: Translocation t(7;19)(q22;q13)—a recurrent chromosome aberration in pseudomyogenic haemangioendothelioma? Cancer Genet. 2011; 204(4): 211–5. PubMed Abstract | Publisher Full Text

72. Walther C, Tayebwa J, Liljebjörn H, et al.: A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. J Pathol. 2014; 232(5): 534–40. PubMed Abstract | Publisher Full Text

73. Simpson AJ, Booth NA, Moore NR, et al.: Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol. 1991; 44(2): 139–43. PubMed Abstract | Publisher Full Text | Free Full Text

74. Declercq PJ, Gils A: Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost. 2013; 39(4): 356–64. PubMed Abstract | Publisher Full Text

75. Antonescu CR, Chen HW, Zhang L, et al.: ZFP36-FOSB fusion defines a subset of epithelioid hemangiofibroma with atypical features. Genes Chromosomes Cancer. 2014; 53(11): 951–9. PubMed Abstract | Publisher Full Text | Free Full Text

76. Mondesir J, Willekens C, Toutot M, et al.: IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 2016; 7: 171–80. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

77. DiNardo CD, Stein EM, de Boltin S, et al.: Durable Remissions with Invisidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018; 378(25): 2386–98. PubMed Abstract | Publisher Full Text | F1000 Recommendation

78. Stein EM, DiNardo CD, Pollyea DA, et al.: Enasidinib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017; 130(6): 722–31. PubMed Abstract | Publisher Full Text | F1000 Recommendation

79. Schumacher T, Bunse L, Pusch S, et al.: A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014; 512(7514): 324–7. PubMed Abstract | Publisher Full Text | F1000 Recommendation

80. Wine Lee L, Goff KL, Lam JM, et al.: Treatment of pediatric pyogenic granulomas using β-adrenergic receptor antagonists. Pediatr Dermatol. 2014; 31(2): 203–7. PubMed Abstract | Publisher Full Text

81. Al-Olabi L, Polubothu S, Dowsett K, et al.: Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Invest. 2018; 128(11): 5185. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation
Open Peer Review

Current Referee Status: ✔ ✔

Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

1. **Douglas A. Marchuck** Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, USA
   *Competing Interests:* No competing interests were disclosed.

2. **Joyce Bischoff** Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
   *Competing Interests:* No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com